SynthesisFrontiers in immunology2021

Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.

Zhao Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.